2026 Q2 - tulosraportti
48 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 6 148 | - | - | ||
| 6 902 | - | - | ||
| 1 | - | - | ||
| 915 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sittenPeople hold because they know what they own. Downturn does not matter for us who hold. No turnover and we still know what we own,Circio
Aside from the clumsy phrasing, it's actually right. The trading volume every time the share price is attempted to be pushed down is microscopic.
·1 t sitten · MuokattuFor 7 months ago Circio entered into an agreement with Japanese United Immunity. The collaboration was to test P-LNP delivery technology targeting myeloid cells, such as macrophages and dendritic cells. P-LNP P-LNP is designed to selectively deliver RNA- and DNA-based therapeutics to macrophages and dendritic cells. Unlike conventional LNPs, P-LNP replaces polyethylene glycol (PEG)-lipids with CHP, reducing concerns associated with anti-PEG antibodies and the accelerated blood clearance (ABC) effect. This allows for multiple repeated dosing with P-LNP. P-LNP is useful to engineer macrophages and dendritic cells using RNA or DNA in vivo. In vivo CAR-M. Now United I is coming with a presentation of P-LNP. See attachmentSITC 2026 - abstract no. 237 - oral presentation. Abstracts are released on November 03. Abstract #237 Presents Friday, Nov. 6 Oral Top 150 🎗 Myeloid-selective P-LNP enables in vivo engineering of GPC3-targeted CAR macrophages, resulting in robust tumor control and antitumor macrophage reprogramming Presenting Author Takatoshi Soga – United Immunity, Co., Ltd. Authors Takatoshi Soga, Yasunari Haseda, Mina Tsukamoto, Nami Mizoguchi, Ayaka Matsumoto, Shingo Iioka, Tomoyo Koga, Yasuhiro Nagai, Tadashi Inoue, Naozumi Harada Primary Category Cellular Therapies Abstract Type Regular
·1 t sittenIt has been a long time since I saw it this calm :) But there will probably be other days before too long, one would hope :) Good luck everyone! Little action on the rest of the Oslo Børs as well, so is probably not the worst place to be in something that goes sideways?
So much is happening around Circio that it is easy to lose one's head. That exciting things are happening does not exclude that Things Take Time.
1 t sittenJulkaisu on poistettu.Do you not see from the volume that this is nonsense? Ultrabull here Good luck, everyone
·2 t sittenIt doesn't take much imagination to understand that day traders need to create fluctuations to make a few percent every day. What I don't understand is those who sell if the price drops a few percent? We clearly see that both jv7 and Bypaxx are doing what they can to spread fear. No news, so someone must clearly be manipulating to create fluctuations. If the small core of day traders fail to create fluctuations, this will die out on its own. Sit tight!
Yes, that was a good answer on how the trading is. Very thin and very algo-driven by a few - which preferably pull it upwards within the gain schedule you describe. All in all, 10.. strengthens One can say that much positive has been described and that there are many irons in the fire that can be drivers. That is also the reason why it has become a longer major double top. It has been cultivated over time, fire and iron on better volume than these days. But it signals that Circio also has a charm leg (which thus finished in the spring). One thing is mouse data, another thing is human - perhaps more for aav than for the many other cancer drugs with payload or other that are more definite/clear language than clever manipulations of biology. So mice and humans can perhaps! be more different in that regard - among other things by lab mice being the world's healthiest mice relative to patients who are unhealthy/have deviations.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
48 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenPeople hold because they know what they own. Downturn does not matter for us who hold. No turnover and we still know what we own,CircioAside from the clumsy phrasing, it's actually right. The trading volume every time the share price is attempted to be pushed down is microscopic.
- ·1 t sitten · MuokattuFor 7 months ago Circio entered into an agreement with Japanese United Immunity. The collaboration was to test P-LNP delivery technology targeting myeloid cells, such as macrophages and dendritic cells. P-LNP P-LNP is designed to selectively deliver RNA- and DNA-based therapeutics to macrophages and dendritic cells. Unlike conventional LNPs, P-LNP replaces polyethylene glycol (PEG)-lipids with CHP, reducing concerns associated with anti-PEG antibodies and the accelerated blood clearance (ABC) effect. This allows for multiple repeated dosing with P-LNP. P-LNP is useful to engineer macrophages and dendritic cells using RNA or DNA in vivo. In vivo CAR-M. Now United I is coming with a presentation of P-LNP. See attachmentSITC 2026 - abstract no. 237 - oral presentation. Abstracts are released on November 03. Abstract #237 Presents Friday, Nov. 6 Oral Top 150 🎗 Myeloid-selective P-LNP enables in vivo engineering of GPC3-targeted CAR macrophages, resulting in robust tumor control and antitumor macrophage reprogramming Presenting Author Takatoshi Soga – United Immunity, Co., Ltd. Authors Takatoshi Soga, Yasunari Haseda, Mina Tsukamoto, Nami Mizoguchi, Ayaka Matsumoto, Shingo Iioka, Tomoyo Koga, Yasuhiro Nagai, Tadashi Inoue, Naozumi Harada Primary Category Cellular Therapies Abstract Type Regular
- ·1 t sittenIt has been a long time since I saw it this calm :) But there will probably be other days before too long, one would hope :) Good luck everyone! Little action on the rest of the Oslo Børs as well, so is probably not the worst place to be in something that goes sideways?So much is happening around Circio that it is easy to lose one's head. That exciting things are happening does not exclude that Things Take Time.
- 1 t sittenJulkaisu on poistettu.Do you not see from the volume that this is nonsense? Ultrabull here Good luck, everyone
- ·2 t sittenIt doesn't take much imagination to understand that day traders need to create fluctuations to make a few percent every day. What I don't understand is those who sell if the price drops a few percent? We clearly see that both jv7 and Bypaxx are doing what they can to spread fear. No news, so someone must clearly be manipulating to create fluctuations. If the small core of day traders fail to create fluctuations, this will die out on its own. Sit tight!Yes, that was a good answer on how the trading is. Very thin and very algo-driven by a few - which preferably pull it upwards within the gain schedule you describe. All in all, 10.. strengthens One can say that much positive has been described and that there are many irons in the fire that can be drivers. That is also the reason why it has become a longer major double top. It has been cultivated over time, fire and iron on better volume than these days. But it signals that Circio also has a charm leg (which thus finished in the spring). One thing is mouse data, another thing is human - perhaps more for aav than for the many other cancer drugs with payload or other that are more definite/clear language than clever manipulations of biology. So mice and humans can perhaps! be more different in that regard - among other things by lab mice being the world's healthiest mice relative to patients who are unhealthy/have deviations.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 6 148 | - | - | ||
| 6 902 | - | - | ||
| 1 | - | - | ||
| 915 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
48 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenPeople hold because they know what they own. Downturn does not matter for us who hold. No turnover and we still know what we own,CircioAside from the clumsy phrasing, it's actually right. The trading volume every time the share price is attempted to be pushed down is microscopic.
- ·1 t sitten · MuokattuFor 7 months ago Circio entered into an agreement with Japanese United Immunity. The collaboration was to test P-LNP delivery technology targeting myeloid cells, such as macrophages and dendritic cells. P-LNP P-LNP is designed to selectively deliver RNA- and DNA-based therapeutics to macrophages and dendritic cells. Unlike conventional LNPs, P-LNP replaces polyethylene glycol (PEG)-lipids with CHP, reducing concerns associated with anti-PEG antibodies and the accelerated blood clearance (ABC) effect. This allows for multiple repeated dosing with P-LNP. P-LNP is useful to engineer macrophages and dendritic cells using RNA or DNA in vivo. In vivo CAR-M. Now United I is coming with a presentation of P-LNP. See attachmentSITC 2026 - abstract no. 237 - oral presentation. Abstracts are released on November 03. Abstract #237 Presents Friday, Nov. 6 Oral Top 150 🎗 Myeloid-selective P-LNP enables in vivo engineering of GPC3-targeted CAR macrophages, resulting in robust tumor control and antitumor macrophage reprogramming Presenting Author Takatoshi Soga – United Immunity, Co., Ltd. Authors Takatoshi Soga, Yasunari Haseda, Mina Tsukamoto, Nami Mizoguchi, Ayaka Matsumoto, Shingo Iioka, Tomoyo Koga, Yasuhiro Nagai, Tadashi Inoue, Naozumi Harada Primary Category Cellular Therapies Abstract Type Regular
- ·1 t sittenIt has been a long time since I saw it this calm :) But there will probably be other days before too long, one would hope :) Good luck everyone! Little action on the rest of the Oslo Børs as well, so is probably not the worst place to be in something that goes sideways?So much is happening around Circio that it is easy to lose one's head. That exciting things are happening does not exclude that Things Take Time.
- 1 t sittenJulkaisu on poistettu.Do you not see from the volume that this is nonsense? Ultrabull here Good luck, everyone
- ·2 t sittenIt doesn't take much imagination to understand that day traders need to create fluctuations to make a few percent every day. What I don't understand is those who sell if the price drops a few percent? We clearly see that both jv7 and Bypaxx are doing what they can to spread fear. No news, so someone must clearly be manipulating to create fluctuations. If the small core of day traders fail to create fluctuations, this will die out on its own. Sit tight!Yes, that was a good answer on how the trading is. Very thin and very algo-driven by a few - which preferably pull it upwards within the gain schedule you describe. All in all, 10.. strengthens One can say that much positive has been described and that there are many irons in the fire that can be drivers. That is also the reason why it has become a longer major double top. It has been cultivated over time, fire and iron on better volume than these days. But it signals that Circio also has a charm leg (which thus finished in the spring). One thing is mouse data, another thing is human - perhaps more for aav than for the many other cancer drugs with payload or other that are more definite/clear language than clever manipulations of biology. So mice and humans can perhaps! be more different in that regard - among other things by lab mice being the world's healthiest mice relative to patients who are unhealthy/have deviations.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 6 148 | - | - | ||
| 6 902 | - | - | ||
| 1 | - | - | ||
| 915 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt